FRAZIER LIFESCIENCES ACQUISITION CORPORATION

All News Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
19.81 ^EUR	-3.37%		-9.38%	+77.35%

05-15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
05-09	Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Starts NewAmsterdam Pharma With Buy Rating	05-15	MT
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	05-09	MT
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	05-09	GL
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05-03	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05-03	AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	05-02	GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	05-02	AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	04-09	GL
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	04-09	CI
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	04-01	MT
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	04-01	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	04-01	AQ
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	04-01	CI
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	03-27	MT
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	03-25	GL
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	03-14	MT
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	03-12	GL
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	03-12	CI
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	02-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

All News

Filters